The life sciences ecosystem in Maryland’s Montgomery County continues its growth with the July 21 opening of Bora Biologics’ drug substance manufacturing facility in Rockville.
“Companies like Bora Pharmaceuticals are what makes Maryland a global leader in the life sciences. They bring talent, innovation, and a commitment to delivering transformative treatment to patients,” said Maryland Commerce Secretary Harry Coker Jr. “We are thrilled that Bora has once again chosen Maryland as they continue to grow and serve patients around the world.”
Bora, a Taiwan-based global pharmaceutical company and contract development and manufacturing organization (CDMO), established operations in Montgomery County through its acquisition of MacroGenics’ GMP manufacturing operations and biologics manufacturing facility in Rockville. The $122.5 million transaction includes a state-of-the-art biologics manufacturing facility and associated operations. The facility includes FDA-approved manufacturing capabilities supporting both clinical and commercial-stage biologics production.
Bora is retaining the 140 employees who previously worked at the site for MacroGenics and plans to add more jobs and capital investment in the near future. The company has operated an 87,000-square-foot cGMP facility in Baltimore since 2024.
Click here to read the rest of the article written by Anne Cosgrove over at Business Facilities
